← Leaderboards
Roger L Kaspar
Somagenics, Inc.
$10,015,316
Attributed
$11,395,316
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–16$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$10,996,223 · 12
FDA$399,093 · 1
By mechanism
R44$5,487,953 · 2
RC2$2,760,000 · 1
R43$2,748,270 · 9
R01$399,093 · 1
Top collaborators
- Christopher H Contag2 shared
Others in their field
Top investigators on “Skin Disorder”
- David Heimbrook · Leidos Biomedical Research, Inc.$55,577,351
- Donald Ym Leung · University Of Colorado Denver$54,023,403
- David S Perlin · Hackensack University Medical Center$40,879,335
- Elaine Fuchs · University Of Chicago$38,106,206
- Jeffrey Charles Lotz · University Of California San Francisco$35,358,407
- David Leung · National Jewish Health$31,859,607
Research focus
Skin DisorderKeratinocyteSkinDesignPainClinical TrialsKeratinImmunocompromised HostEpidermisGene ExpressionMutantIntradermal InjectionDrug FormulationsMouse ModelSmall Interfering RnaTechnologyGenesRna InterferenceToxicologyAnimal ModelMutationCellsIontophoresisImage
Grant awards (19)
Topical sirolimus Phase 1b trial for pachyonychia congenita (IND number 117347)$199,697
R01 · FY2016 · FD · contact PI
Topical sirolimus Phase 1b trial for pachyonychia congenita (IND number 117347)$199,396
R01 · FY2015 · FD · contact PI
Development of topical formulations for delivery of next generation mTOR inhibito$225,000
R43 · FY2014 · AR · contact PI
Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs$1,045,754
R44 · FY2013 · AR · contact PI
Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs$973,429
R44 · FY2012 · AR · contact PI
Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs$2,087,970
R44 · FY2011 · AR · contact PI
Delivery of biologically active nucleic acids to epidermal cells$1,256,097
RC2 · FY2010 · AR · contact PI
Evaluation of siRNA uptake and functional activity in a human organotypic skin mo$340,859
R43 · FY2010 · AR · contact PI
Delivery of biologically active nucleic acids to epidermal cells$1,503,903
RC2 · FY2009 · AR · contact PI
Development of siRNA delivery methodologies using in vivo imaging models$1,380,800
R44 · FY2009 · AR · contact PI
Pachyonychia congenita clinical trial using therapeutic siRNAs$312,655
R43 · FY2008 · AR · contact PI
Development of topical rapamycin as a novel treatment for skin disorders$226,281
R43 · FY2008 · AR · contact PI
In vivo imaging models for evaluating siRNA delivery to skin$148,215
R43 · FY2008 · AR · contact PI
Development of RNA-based topical psoriasis inhibitors$285,944
R43 · FY2005 · AR
Inhibition of hepatitis C by RNA Lassos$299,987
R43 · FY2004 · AI
Development of siRNA libraries for antiviral discovery$294,659
R43 · FY2004 · AI
Redirection of Fas splicing as a cancer therapy$22,676
R43 · FY2004 · CA
Inhibition of hepatitis C by RNA Lassos$299,978
R43 · FY2003 · AI
Redirection of Fas splicing as a cancer therapy$292,016
R43 · FY2003 · CA